RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. (RIFUND-MS)
RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. A Randomized Phase 3 Study Comparing Rituximab With Dimethyl Fumarate in Early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.
Sponsor: Anders Svenningsson
A PHASE3 clinical study on Multiple Sclerosis, Relapsing-Remitting, this trial is completed. The trial is conducted by Anders Svenningsson and has accumulated 11 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
▶ Show 6 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
Mar 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Nov 2017 [monthly]
Recruiting PHASE3
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anders Svenningsson
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Borås, Sweden , Falun, Sweden , Gothenburg, Sweden , Gävle, Sweden , Helsingborg, Sweden , Karlstad, Sweden , Kungsbacka, Sweden , Linköping, Sweden , Nyköping, Sweden , Stockholm, Sweden and 4 more locations